WELL Health Technologies Forecast, price target & analysts
WELL Health Technologies Target price 2025 - Analyst rating & recommendation
WELL Health Technologies Classifications & Recommendation:
WELL Health Technologies Price Target
| Target Price | CAD8.68 |
| Price | CAD5.74 |
| Potential |
51.19%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target WELL Health Technologies 2026 .
The average WELL Health Technologies target price is CAD8.68.
This is
51.19%
register free of charge
CAD11.00
91.64%
register free of charge
CAD7.00
21.95%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend WELL Health Technologies to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the WELL Health Technologies stock has an average upside potential 2026 of
51.19%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million CAD | 776.05 | 989.77 |
| 36.35% | 27.54% | |
| EBITDA Margin | 13.13% | 12.87% |
| 8.52% | 1.97% | |
| Net Margin | 0.00% | 4.67% |
| 100.00% |
14 Analysts have issued a sales forecast WELL Health Technologies 2024 . The average WELL Health Technologies sales estimate is
This results in the following potential growth metrics:
14 Analysts have issued an WELL Health Technologies EBITDA forecast 2024. The average WELL Health Technologies EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 WELL Health Technologies Analysts have issued a net profit forecast 2024. The average WELL Health Technologies net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share CAD | 0.00 | 0.19 |
| 100.00% | ||
| P/E | 30.93 | |
| EV/Sales | 1.85 |
9 Analysts have issued a WELL Health Technologies forecast for earnings per share. The average WELL Health Technologies <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the WELL Health Technologies stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
WELL Health Technologies...
Current WELL Health Technologies Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| TD COWEN | Locked ➜ Locked | Locked | Dec 15 2024 |
| CIBC CAPITAL MARKETS | Locked ➜ Locked | Locked | Dec 15 2024 |
| SCOTIABANK GBM | Locked ➜ Locked | Locked | Dec 15 2024 |
| RAYMOND JAMES LTD. | Locked ➜ Locked | Locked | Dec 15 2024 |
| CORMARK SECURITIES INC. | Locked ➜ Locked | Locked | Dec 12 2024 |
| CANACCORD GENUITY | Locked ➜ Locked | Locked | Dec 11 2024 |
| VENTUM FINANCIAL CORP. | Locked ➜ Locked | Locked | Dec 11 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
TD COWEN: Locked ➜ Locked
|
Dec 15 2024 |
|
Locked
CIBC CAPITAL MARKETS: Locked ➜ Locked
|
Dec 15 2024 |
|
Locked
SCOTIABANK GBM: Locked ➜ Locked
|
Dec 15 2024 |
|
Locked
RAYMOND JAMES LTD.: Locked ➜ Locked
|
Dec 15 2024 |
|
Locked
CORMARK SECURITIES INC.: Locked ➜ Locked
|
Dec 12 2024 |
|
Locked
CANACCORD GENUITY: Locked ➜ Locked
|
Dec 11 2024 |
|
Locked
VENTUM FINANCIAL CORP.: Locked ➜ Locked
|
Dec 11 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
